Skip to main page content
U.S. flag

An official website of the United States government

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Results by year

1970
2025

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1970 4
1971 1
1972 2
1973 5
1974 3
1975 8
1976 4
1977 8
1978 3
1979 8
1980 9
1981 9
1982 7
1983 16
1984 10
1985 16
1986 13
1987 5
1988 23
1989 22
1990 23
1991 19
1992 27
1993 22
1994 23
1995 26
1996 24
1997 26
1998 24
1999 19
2000 26
2001 36
2002 31
2003 23
2004 31
2005 27
2006 21
2007 23
2008 30
2009 27
2010 32
2011 18
2012 28
2013 31
2014 23
2015 29
2016 27
2017 24
2018 28
2019 34
2020 32
2021 24
2022 25
2023 22
2024 16
2025 0

Publication date

Text availability

Article attribute

Article type

Additional filters

Search Results

1,029 results

Results by year

Filters applied: . Clear all
Page 1
Malignant hyperthermia: a review.
Rosenberg H, Pollock N, Schiemann A, Bulger T, Stowell K. Rosenberg H, et al. Orphanet J Rare Dis. 2015 Aug 4;10:93. doi: 10.1186/s13023-015-0310-1. Orphanet J Rare Dis. 2015. PMID: 26238698 Free PMC article. Review.
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to potent volatile anesthetic gases such as halothane, sevoflurane, desflurane, isoflurane and the depolarizing muscle relaxant succinylcholine, a
Malignant hyperthermia (MH) is a pharmacogenetic disorder of skeletal muscle that presents as a hypermetabolic response to pot
Pathophysiology and Treatment of Malignant Hyperthermia.
Gregory H, Weant KA. Gregory H, et al. Adv Emerg Nurs J. 2021 Apr-Jun 01;43(2):102-110. doi: 10.1097/TME.0000000000000344. Adv Emerg Nurs J. 2021. PMID: 33915557 Review.
Malignant hyperthermia (MH) is caused by a genetic disorder of the skeletal muscle that induces a hypermetabolic response when patients are exposed to a triggering agent such as volatile inhaled anesthetics or depolarizing neuromuscular blockers. Symptoms of MH incl
Malignant hyperthermia (MH) is caused by a genetic disorder of the skeletal muscle that induces a hypermetabolic response when
Malignant Hyperthermia.
Kaur H, Katyal N, Yelam A, Kumar K, Srivastava H, Govindarajan R. Kaur H, et al. Mo Med. 2019 Mar-Apr;116(2):154-159. Mo Med. 2019. PMID: 31040503 Free PMC article. Review.
Malignant Hyperthermia (MH) is a life-threatening pharmacogenetic disorder which results from exposure to volatile anesthetic agents and depolarizing muscle relaxants. It manifests as a hypermetabolic response resulting in tachycardia, tachypnea, hyperthermia
Malignant Hyperthermia (MH) is a life-threatening pharmacogenetic disorder which results from exposure to volatile anesthetic
Fever--an update.
Becker JH, Wu SC. Becker JH, et al. J Am Podiatr Med Assoc. 2010 Jul-Aug;100(4):281-90. doi: 10.7547/1000281. J Am Podiatr Med Assoc. 2010. PMID: 20660880 Review.
Mutations in RYR1 in malignant hyperthermia and central core disease.
Robinson R, Carpenter D, Shaw MA, Halsall J, Hopkins P. Robinson R, et al. Hum Mutat. 2006 Oct;27(10):977-89. doi: 10.1002/humu.20356. Hum Mutat. 2006. PMID: 16917943 Review.
Mutations in the gene have been found in association with several diseases: the pharmacogenetic disorder, malignant hyperthermia (MH); and three congenital myopathies, including central core disease (CCD), multiminicore disease (MmD), and in an isolated case of a co …
Mutations in the gene have been found in association with several diseases: the pharmacogenetic disorder, malignant hyperthermia
Malignant hyperthermia.
Hopkins PM, Gupta PK, Bilmen JG. Hopkins PM, et al. Handb Clin Neurol. 2018;157:645-661. doi: 10.1016/B978-0-444-64074-1.00038-0. Handb Clin Neurol. 2018. PMID: 30459030 Review.
Malignant hyperthermia (MH) is a form of heat illness caused by increased heat generation exceeding the body's capacity for heat loss. ...
Malignant hyperthermia (MH) is a form of heat illness caused by increased heat generation exceeding the body's capacity for he
Malignant Hyperthermia.
Pinyavat T, Riazi S, Deng J, Slessarev M, Cuthbertson BH, Ibarra Moreno CA, Jerath A. Pinyavat T, et al. Crit Care Med. 2024 Dec 1;52(12):1934-1940. doi: 10.1097/CCM.0000000000006401. Epub 2024 Aug 22. Crit Care Med. 2024. PMID: 39171998 Review.
OBJECTIVES: A narrative expert review aiming to summarize the clinical epidemiology and management of critically ill patients with malignant hyperthermia (MH). DATA SOURCES: Medline searches were conducted to identify relevant articles describing the epidemiology, p …
OBJECTIVES: A narrative expert review aiming to summarize the clinical epidemiology and management of critically ill patients with malign
Epidemiological and clinical features of malignant hyperthermia: A scoping review.
Cong Z, Wan T, Wang J, Feng L, Cao C, Li Z, Wang X, Han Y, Zhou Y, Gao Y, Zhang J, Qu Y, Guo X. Cong Z, et al. Clin Genet. 2024 Mar;105(3):233-242. doi: 10.1111/cge.14475. Epub 2023 Dec 26. Clin Genet. 2024. PMID: 38148504 Review.
Malignant hyperthermia (MH) is a potentially fatal inherited pharmacogenetic disorder related to pathogenic variants in the RYR1, CACNA1S, or STAC3 genes. ...The most frequent initial clinical signs included hyperthermia, sinus tachycardia, and hypercarbia. T
Malignant hyperthermia (MH) is a potentially fatal inherited pharmacogenetic disorder related to pathogenic variants in the RY
Malignant Hyperthermia Update.
Ellinas H, Albrecht MA. Ellinas H, et al. Anesthesiol Clin. 2020 Mar;38(1):165-181. doi: 10.1016/j.anclin.2019.10.010. Anesthesiol Clin. 2020. PMID: 32008650 Review.
Malignant hyperthermia (MH) is a rare but potentially lethal skeletal muscle disorder affecting calcium release channels. ...
Malignant hyperthermia (MH) is a rare but potentially lethal skeletal muscle disorder affecting calcium release channels. ...
1,029 results